Phoenix Health Services LLC

phxhealthohio.com

Phoenix Health Services, a small family owned and operated healthcare company, operates two skilled nursing facilities in Northeast Ohio. Sunrise Pointe Nursing & Rehab in Maple Heights and Windsong Nursing & Rehab in Akron. Check out our website to learn more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

news image

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

INDUSTRIAL IMPACT

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

CELL AND GENE THERAPY

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

news image

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More
news image

MEDTECH

IBM RESEARCH AND ARCTORIS ACCELERATE CLOSED LOOP DRUG DISCOVERY WITH AI AND CLOUD

Arctoris | September 14, 2021

IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is able to perform highly accurate reaction predictions using its powerful AI. Opt...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

INDUSTRIAL IMPACT

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

CELL AND GENE THERAPY

ELEVATEBIO AND THE UNIVERSITY OF PITTSBURGH ANNOUNCE CREATION OF PITT BIOFORGE BIOMANUFACTURING CENTER AT HAZELWOOD GREEN

ElevateBio | August 26, 2022

ElevateBio, LLC and the University of Pittsburgh announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies. Through this agreement, ElevateBio will locate one of its next BaseCamp process development and Good Manufacturing Practice manufacturing facilities in Pittsburgh, fully equipped with its enabling technologies, including gene editing, induced pluripotent stem cell and cell, vector, and protein engineer...

Read More

Resources

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

resource image

CELL AND GENE THERAPY

A New Generation of Cancer Immunotherapies

Whitepaper

resource image

MEDTECH

Biotech in 2022

Article

resource image

CELL AND GENE THERAPY

Automated Microbioreactor Technology

Video

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

resource image

CELL AND GENE THERAPY

A New Generation of Cancer Immunotherapies

Whitepaper

resource image

MEDTECH

Biotech in 2022

Article

resource image

CELL AND GENE THERAPY

Automated Microbioreactor Technology

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us